A Low Dose of Naloxone Added to Ropivacaine Prolongs Femoral Nerve Blockade

A Low Dose of Naloxone Added to Ropivacaine Prolongs Femoral Nerve Blockade: A Randomized Clinical Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0004632

Enrollment

Registered

2020-01-16

Start date

2020-01-17

Completion date

Unknown

Last updated

2020-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Naloxone As a pure antagonist of opioids, high doses may reverse analgesia or cause analgesia, but low doses may have analgesic effects and reduce the side effects associated with opioids. The

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: American Society of Anesthesiologists Body Rating Classifications I, II, III Patients over 18 years old and 80 years old who agreed to participate in the study Patients undergoing knee joint replacement surgery

Exclusion criteria

Exclusion criteria: Patients with infection at the site of blockade Patients with chronic opiate dependence Patients with pathological obesity (BMI> 35) Patients with a preceding neurological deficit Bleeding patients Patients with allergy to ropivacaine, naloxone Patients with Uncontrolled Diabetes pregnant woman A psychiatric problem Patient rejection

Design outcomes

Primary

Measure	Time frame
Pain relief period	—

Secondary

Measure	Time frame
Satisfaction score;Side effect	—

Countries

Korea, Republic of

Contacts

Public ContactSangYoong Park

Dong-A University Hospital

Outcome results